Posted: August 15, 2019 | Word Count: 143
Blood cancers account for more than 40 percent of all childhood cancers, and most children are treated with the same toxic combinations of chemotherapies developed decades ago. Though there has been significant progress in advancing new therapies for adults with cancer, only four oncology drugs have been approved for first-use in children over the past four decades. While many children survive acute lymphoblastic leukemia, the most common type of pediatric blood cancer, the current treatments are harsh and outdated and the long-term effects can create severe life-threatening complications. That’s why The Leukemia & Lymphoma Society (LLS) is more than doubling their investment in leading-edge research to find safer, lifesaving therapies for children, teens and young adults with blood cancers, while expanding our services for children and their families, and planning an unprecedented LLS-led global precision medicine clinical trial for children with acute leukemia.
This article is available to download for free use in print and online publications. If you must edit the article, please include at least one brand reference. All articles must retain the (BPT) or Brandpoint byline.
Download this Article